Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Presidential Punt On Drug Pricing

Executive Summary

White House confirms that it will not be pushing major drug pricing provisions to help pay for its next multi-trillion dollar legislative proposal. That sounds like good news for industry – but don’t pop the champagne just yet.

You may also be interested in...



Biden Budget Gives Drug Pricing Reform A Spotlight But No Specifics

Approach leaves policy development to Congress. The President understands the need to build consensus around specific policies to achieve his goals, White House Office of Management and Budget Acting Director Shalanda Young explains.

CMS’ Brooks-LaSure: Early Action Impacting Pharma Likely To Focus On Legacy Trump Policies

Chiquita Brooks-LaSure’s nomination was approved in a 55-44 vote, with five Republicans joining Democrats in favor. Her confirmation clears the way for other appointments to key positions at the agency, such as the directors of the centers for Medicare and Medicaid.  

Pharma Resisting Efforts To Send Drug Pricing Savings To US Budget ‘Black Hole’ – Pfizer’s Bourla

Biopharma draws a line in the sand on drug pricing reform and offers to come to the table, but given the fracturing support for Rx legislation within the Democratic caucus, industry may not have as much need to negotiate with Congress. More detail on industry’s latest proposals for lowering costs may come in the second half.

Related Content

Topics

UsernamePublicRestriction

Register

PS144237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel